CLDX Stock Overview
A biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Celldex Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$41.24 |
| 52 Week High | US$53.18 |
| 52 Week Low | US$22.11 |
| Beta | 1.56 |
| 11 Month Change | 14.30% |
| 3 Month Change | 16.93% |
| 1 Year Change | 62.04% |
| 33 Year Change | -25.30% |
| 5 Year Change | 1,800.46% |
| Change since IPO | -63.97% |
Recent News & Updates
Recent updates
Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns
Jun 07
We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth
Jun 05We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth
Jul 07An Intrinsic Calculation For Celldex Therapeutics, Inc. (NASDAQ:CLDX) Suggests It's 34% Undervalued
Apr 21Companies Like Celldex Therapeutics (NASDAQ:CLDX) Are In A Position To Invest In Growth
Feb 27We're Not Very Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Rate
Sep 07Celldex begins dosing in mid-stage study of barzolvolimab for skin disorder
Jul 21Celldex: Barzolvolimab Plus Bispecific Antibodies Advancement
Jul 14Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans
May 25Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 31%?
Feb 03Celldex: Pipeline Of Drug Candidates Is Worth A Look
Feb 01Celldex Therapeutics: A Best Price-Positioned Biotech Stock As Seen By Market-Makers
Sep 23We Think Celldex Therapeutics (NASDAQ:CLDX) Can Easily Afford To Drive Business Growth
Sep 15Celldex: Powerful Medicines To Yield Further Upsides
Jul 08Here's Why We're Not Too Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Situation
May 12Shareholder Returns
| CLDX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.6% | 1.4% | 2.6% |
| 1Y | 62.0% | 23.1% | 30.5% |
Return vs Industry: CLDX exceeded the US Biotechs industry which returned 23.1% over the past year.
Return vs Market: CLDX exceeded the US Market which returned 30.5% over the past year.
Price Volatility
| CLDX volatility | |
|---|---|
| CLDX Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CLDX has not had significant price volatility in the past 3 months.
Volatility Over Time: CLDX's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 160 | Anthony Marucci | www.celldex.com |
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company’s clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity.
Celldex Therapeutics, Inc. Fundamentals Summary
| CLDX fundamental statistics | |
|---|---|
| Market cap | US$2.73b |
| Earnings (TTM) | -US$150.22m |
| Revenue (TTM) | US$8.30m |
329.2x
P/S Ratio-18.2x
P/E RatioIs CLDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLDX income statement (TTM) | |
|---|---|
| Revenue | US$8.30m |
| Cost of Revenue | US$120.94m |
| Gross Profit | -US$112.63m |
| Other Expenses | US$37.58m |
| Earnings | -US$150.22m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.27 |
| Gross Margin | -1,356.56% |
| Net Profit Margin | -1,809.18% |
| Debt/Equity Ratio | 0% |
How did CLDX perform over the long term?
See historical performance and comparison